Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Neurobiol ; 57(3): 1778, 2020 03.
Article in English | MEDLINE | ID: mdl-31939145

ABSTRACT

In the original version of the paper, the name of one of the contributing authors, Dr. Mundackal S. Divya (orcid:0000-0002-2869-7191).

2.
Mol Neurobiol ; 57(3): 1768-1777, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31834602

ABSTRACT

Huntington's disease (HD) is a neurodegenerative late-onset genetic disorder caused by CAG expansions in the coding region of the Huntingtin (HTT) gene, resulting in a poly-glutamine (polyQ) expanded HTT protein. Considerable efforts have been devoted for studying HD and other polyQ diseases using animal models and cell culture systems, but no treatment currently exists. Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) offer an elegant solution for modeling human diseases. However, as embryonic or rejuvenated cells, respectively, these pluripotent stem cells (PSCs) do not recapitulate the late-onset feature of the disease. Here, we applied a robust and rapid differentiation protocol to derive electrophysiologically active striatal GABAergic neurons from human wild-type (WT) and HD ESCs and iPSCs. RNA-seq analyses revealed that HD and WT PSC-derived neurons are highly similar in their gene expression patterns. Interestingly, ectopic expression of Progerin in both WT and HD neurons exacerbated the otherwise non-significant changes in gene expression between these cells, revealing IGF1 and genes involved in neurogenesis and nervous system development as consistently altered in the HD cells. This work provides a useful tool for modeling HD in human PSCs and reveals potential molecular targets altered in HD neurons.


Subject(s)
Huntington Disease/genetics , Induced Pluripotent Stem Cells/metabolism , Lamin Type A/metabolism , Neurons/cytology , Pluripotent Stem Cells/metabolism , Transcription, Genetic , Cell Differentiation/physiology , Embryonic Stem Cells/metabolism , Humans , Huntingtin Protein/genetics , Huntingtin Protein/metabolism , Huntington Disease/metabolism
3.
Proc Natl Acad Sci U S A ; 109(52): E3687-95, 2012 Dec 26.
Article in English | MEDLINE | ID: mdl-23236169

ABSTRACT

Stress induces long-lasting changes in neuronal gene expression and cholinergic neurotransmission, but the underlying mechanism(s) are incompletely understood. Here, we report that chromatin structure and histone modifications are causally involved in this transcriptional memory. Specifically, the AChE gene encoding the acetylcholine-hydrolyzing enzyme acetylcholinesterase is known to undergo long-lasting transcriptional and alternative splicing changes after stress. In mice subjected to stress, we identified two alternative 5' exons that were down-regulated after stress in the hippocampus, accompanied by reduced acetylation and elevated trimethylation of H3K9 at the corresponding promoter. These effects were reversed completely by daily administration of the histone deacetylase (HDAC) inhibitor sodium butyrate for 1 wk after stress. H3K9 hypoacetylation was associated with a selective, sodium butyrate-reversible promoter accumulation of HDAC4. Hippocampal suppression of HDAC4 in vivo completely abolished the long-lasting AChE-related and behavioral stress effects. Our findings demonstrate long-lasting stress-inducible changes in AChE's promoter choices, identify the chromatin changes that support this long-term transcriptional memory, and reveal HDAC4 as a mediator of these effects in the hippocampus.


Subject(s)
Acetylcholinesterase/genetics , Epigenesis, Genetic , Histone Deacetylases/metabolism , Stress, Physiological/genetics , Transcription, Genetic , Acetylcholinesterase/metabolism , Animals , Chromatin/metabolism , DNA Methylation/genetics , Epigenesis, Genetic/drug effects , Exons/genetics , Gene Silencing/drug effects , Hippocampus/cytology , Histone Deacetylase Inhibitors/pharmacology , Male , Mice , Neurons/drug effects , Neurons/enzymology , Promoter Regions, Genetic , Stress, Physiological/drug effects , Swimming , Transcription, Genetic/drug effects
4.
Nucleus ; 3(5): 433-41, 2012.
Article in English | MEDLINE | ID: mdl-22892726

ABSTRACT

Polyglutamine (PolyQ)-related diseases are dominant late-onset genetic disorders that are manifested by progressive neurodegeneration, leading to behavioral and physical impairments. An increased body of evidence suggests that chromatin structure and epigenetic regulation are involved in disease pathology. PolyQ diseases often display an aberrant transcriptional regulation due to the disrupted function of histone-modifying complexes and altered interactions of the polyQ-extended proteins with chromatin-related factors. In this review we describe recent findings relating to the role of chromatin in polyQ diseases. We discuss the involvement of epigenetic-related factors and chromatin structure in genomic instability of CAG repeats; we describe changes in the expression and regulation of chromatin-related enzymes and in the levels and patterns of histone modifications in disease state; we illustrate the potential beneficial effects of different histone deacetylase (HDAC) inhibitors for the treatment of polyQ diseases, and we end by describing the potential use of human pluripotent stem cells and their differentiated derivatives for modeling polyQ diseases in vitro. Taken together, these accumulating studies strongly suggest that disrupted chromatin regulation may be directly involved with the pathophysiology of polyQ-related diseases.


Subject(s)
Chromatin/metabolism , Peptides/metabolism , Animals , Brain Diseases/drug therapy , Brain Diseases/metabolism , Brain Diseases/pathology , Genomic Instability , Histone Deacetylase Inhibitors/therapeutic use , Histones/metabolism , Humans , Pluripotent Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...